SOHM Biotech Division
Pioneering the Future
of Precision Medicine
At SOHM, our Biotech Division represents the cutting edge of genetic innovation, where breakthrough science meets real-world therapeutic applications. As part of our comprehensive portfolio of advanced technologies, our biotech initiatives focus on developing transformative solutions that address the most pressing challenges in modern medicine. Our experienced team of scientists, researchers, and innovators—including patent holders in gene editing technology—work at the intersection of molecular biology and therapeutic development. We are accelerating the translation of revolutionary discoveries into clinical realities.
Introducing Our Flagship
Biotechnology Platform
ABBIE Gene Editing
Traditional gene editing creates unwanted DNA breaks that can damage cells. ABBIE™ changes that. Our breakthrough technology integrates genetic material without retroviral vectors, opening new frontiers in precision medicine and therapeutic development.
Gene editing has transformed medicine, but current methods have limitations. When current technologies cut DNA, cells often repair themselves incorrectly, creating unintended changes. ABBIE™ eliminates this risk by inserting genetic material without cutting, like threading a needle instead of breaking the thread.
ABBIE™, standing for A Binding Based Integrase Enzyme, is a gene editing system that offers a refined approach to integrating desired DNA sequences into a cell’s genome. It combines the ease-of-use site specificity of Cas9 protein with retroviral integrase-driven integration of donor DNA sequences into genomic DNA. Unlike traditional methods that rely on double-stranded cutting of DNA, which can trigger cellular repair pathways and potentially lead to unintended edits, ABBIE™ employs a unique guide RNA-targeted integration of the desired DNA sequence. The system also avoids the use of viral vectors.
Precision Integration for
Advanced Therapeutics and Research
At SOHM, we are deeply committed to advancing the real-time benefits of the ABBIE™ gene editing platform. Our experienced team, comprised of seasoned professionals including innovators holding patents in gene editing technology, ensures deep expertise and continuous refinement of the platform’s capabilities. We are strategically focused on forming key partnerships within therapeutic areas such as CAR-T therapy and cancer drug development to rapidly accelerate ABBIE’s clinical and commercial impact. With foundational patents for the ABBIE™ system secured in multiple key regions globally, including South Korea and Europe, we are strengthening our intellectual property position. Furthermore, we are actively investing in the technology’s future, continuously enhancing ABBIE’s capabilities and driving innovation across the broader genome editing landscape.
The ABBIE™ Advantage
Non-Viral
Delivery
Eliminates viral contamination risks and manufacturing complexities that plague current therapies.
No Double-
Stranded Breaks
Prevents the cellular damage response that causes 30-40% of current gene edits to fail.
Large Integration
Capacity
Delivers complete therapeutic genes in a single treatment, not just small corrections.
Targeted and
Precise
Utilizes guide RNA to direct the insertion of DNA sequences to specific locations in the genome, minimizing off-target effects.
High
Efficiency
Achieves consistent results across different cell types, reducing treatment variability
Flexibility
Easily alternating of donor DNA sequence and targeting guide RNA to suit different research or therapeutic needs.
Traceability
Trace components that can potentially enhance safety, control, and streamline regulatory processes, including FDA filings.
The ABBIE™ Potential
Gene
Therapies
Creating CAR-T cells that retain multiple therapeutic functions without the chromosomal instability seen in current methods
Cell
Engineering
Treating sickle cell disease by replacing the entire faulty gene, not just correcting single mutations.
Research
Studying gene function by inserting reporter genes that track cellular behavior in real-time
Manufacturing
Producing therapeutic proteins in engineered cells with predictable, stable output.
The ABBIE™ Assurance 
Why This Matters Now
As personalized medicine advances, we need tools that work reliably across diverse genetic backgrounds. ABBIE™ addresses the fundamental limitations holding back the next generation of genetic therapies.
The Science Behind Safety
By avoiding DNA breaks, ABBIE™ prevents the cellular stress response that can lead to cancer-causing mutations. This approach maintains genomic stability while achieving precise therapeutic modifications.
Write to
SOHM
Send us a message for inquiries,
information, or feedback.